兽研引言：猫过敏管理范式的转变
宠物动物在现代社会中发挥着日益重要的作用（1–3）。犬和猫是全球饲养量最大的宠物之一，为其主人提供了显著的情感、心理和社会益处（4–6）。然而，接触宠物过敏原也是过敏性疾病的主要原因之一，影响相当比例的人群（4），并加剧了过敏性鼻炎和哮喘的全球负担（7）。随着宠物饲养率持续上升（8），接触宠物过敏原的个体数量很可能相应增加。
宠物过敏与广泛的临床表现谱相关，从鼻结膜炎和皮肤症状到哮喘及致敏个体的严重急性发作（7, 9）。猫和犬过敏原是最重要的室内过敏原之一，对毛茸动物的致敏与哮喘患病率增加、疾病严重程度加重以及生活质量受损相关（4, 10）。重要的是，宠物过敏原并不局限于养宠家庭，而是广泛分布于公共和私人室内环境中（11），即使对于不养宠物的个体，完全回避也十分困难（12, 13）。
宠物过敏的发生和严重程度受多种相互作用因素的影响，包括过敏原暴露、上皮屏障完整性、宿主免疫反应和环境决定因素。过敏性致敏并非代表单一疾病机制，而是动物、环境与过敏个体之间复杂相互作用的结果。近期研究强调了这些机制的重要性，并强调需要采取综合方法，同时解决过敏原暴露和宿主易感性两方面的问题（14, 15）。在这一更广泛的框架内，源头导向策略旨在从起源处减少过敏原负荷，并补充已有的患者导向干预措施。
当前的管理主要依赖于过敏原回避、药物治疗和过敏原免疫治疗（AIT），每种方法都有重要的局限性。回避往往不切实际，因为宠物过敏原无处不在，且许多患者不愿与伴侣动物分离。药物治疗可有效控制症状，但不能改变潜在的过敏性疾病。尽管AIT仍是目前唯一可用的疾病修饰治疗，但其在宠物过敏中的作用仍存在争议（5, 16）。与花粉或毒液免疫治疗相比，支持猫和犬AIT的证据基础更为有限，治疗反应似乎更具变异性，且合并哮喘的患者可能出现安全性问题（16–19）。关于宠物AIT的疗效、安全性、患者选择和最佳实施方式仍存在重要问题（5）。因此，仍需要改进的源头导向过敏原减少策略以及更安全、更有效的患者导向免疫调节疗法。已有报道采用低过敏性过敏原衍生物在常规皮下免疫治疗（SCIT）中应用时引起较少的过敏性不良事件（20），或使用淋巴结内免疫治疗（ILIT），其所需注射次数更少、过敏原剂量更低（21）。
宠物过敏相关的挑战因人与宠物之间强烈的情感纽带而进一步复杂化。对许多个体和家庭而言，饲养宠物提供了显著的益处，使移除宠物变得不可取或不可接受。因此，过敏管理的目标已不仅限于症状控制，而是日益涵盖维持人与动物的关系，同时维护患者和动物的健康与福祉。
历史上，管理宠物过敏的努力几乎完全集中在过敏个体身上。然而，近年来出现了一种新范式，即动物本身成为干预的靶标（4）。疫苗接种、饮食过敏原中和、美容策略和遗传学方法的进展为在暴露发生之前减少过敏原的产生、活性和传播创造了机会。这些源头导向方法补充了传统的患者导向疗法，并可能最终实现更有效和可持续的宠物过敏管理。下文我们将讨论这些当前和新兴的策略，它们均旨在降低毛茸动物的致敏潜力。我们特别关注猫，探讨针对过敏原产生、过敏原活性和过敏原脱落的干预措施，并考虑如何将这些方法与已有的患者导向疗法相结合，以减轻疾病负担、改善生活质量、维护人与动物的纽带并确保动物福利。图1和表1展示并列出了猫过敏综合管理策略的概览。
[图：猫过敏综合管理策略的概念概述。Fel d 1 由猫产生，随后]
Table 1. Framework for integrated management of cat allergy.
| Stage | Example intervention | Primary objective |
|---|---|---|
| Allergen production | Vaccination, genetic selection | Reduce allergen generation and biologically active allergen |
| Allergen activity | Vaccination-induced antibodies, dietary anti-Fel d 1 IgY | Reduce biologically active allergen |
| Allergen on fur | Grooming, wipes, sprays, bathing | Reduce surface allergen burden |
| Environmental burden | Cleaning, HEPA filtration | Reduce environmental exposure |
| Human immune response | Allergen immunotherapy, biologics, pharmacotherapy | Increase tolerance and control symptoms |
Fel d 1作为主要靶点
Fel d 1的生物学
Fel d 1是主要的猫过敏原，也是猫过敏个体致敏和过敏症状的主要原因（22, 23）。近95%的猫过敏患者具有针对Fel d 1的特异性IgE抗体，使其成为过敏免疫反应的主要靶点。与许多其他哺乳动物过敏原不同，Fel d 1几乎仅由猫产生，因此是猫过敏原暴露的高度特异性标志物。在结构上，Fel d 1是一种分泌球蛋白，由两条不同的多肽链通过三个二硫键连接形成异二聚体（24–26）。两个异二聚体可通过非共价相互作用进一步结合形成四聚体复合物（25, 27）。尽管其确切的生物学功能仍不确定，但Fel d 1被认为参与信息素运输和猫之间的化学通讯。其位于皮脂腺、唾液腺和肛门腺（28）提示其在参与领地和社交行为的化学信号的产生或传播中发挥作用。在梳理过程中，含有Fel d 1的唾液沉积在皮毛和皮肤上，过敏原从那里变为空气传播并持续释放到环境中。
为何靶向Fel d 1？
若干特征使Fel d 1成为源头导向干预的有吸引力的靶点。首先，它是绝大多数猫过敏个体识别的优势猫过敏原（29）。目前已描述了七种其他次要过敏原（Fel d 2–8）（4, 22, 30）。因此，减少对Fel d 1的暴露预期可使大部分患者受益，而靶向次要过敏原的影响可能较为有限。其次，Fel d 1几乎仅由猫产生，且过敏原在人类暴露发生之前即释放到环境中。这创造了在源头进行干预的独特机会，而非仅治疗致敏个体的下游过敏反应。当前的管理策略——包括过敏原回避、药物治疗和AIT——针对患者，并不改变动物的过敏原产生。相比之下，靶向Fel d 1产生、活性或脱落的干预有可能减少所有与猫接触个体的过敏原暴露。第三，Fel d 1具有若干使其适合源头导向干预的特征。由于该过敏原由有限数量的组织产生，在梳理过程中沉积在皮毛上，随后传播到环境中，因此存在多种机会来减少其产生、中和其生物活性或限制其环境积累。这些特征促进了旨在降低对生物活性Fel d 1暴露的多种策略的开发。
综上所述，Fel d 1在猫过敏中的核心作用、其猫特异性来源以及其对源头导向干预的可及性，使Fel d 1成为新兴过敏管理方法的合理焦点。除了治疗过敏原暴露的后果外，这些策略还旨在从源头减少暴露，代表猫过敏管理中的重大潜力。
Fel d 1的环境暴露与临床相关性
Fel d 1的临床意义不仅取决于其强效致敏性，还取决于其卓越的环境传播和持续存在能力。沉积在皮毛上后，Fel d 1持续释放到毛发、皮屑和微小空气颗粒上，这些颗粒容易分散到室内环境中并附着在衣物、家具、地毯和其他表面上。因此，猫从家中移除后，Fel d 1仍可检测数月（12, 13, 31, 32）。除养猫家庭的直接暴露外，过敏原通过衣物和个人物品的被动运输也促进了Fel d 1的广泛分布。在学校、工作场所、酒店、公共交通和从未有猫出现的其他环境中已检测到可测量的过敏原水平（12, 33）。因此，即使对于自身不养猫的个体，完全避免猫过敏原暴露通常也难以实现。
这种广泛的传播解释了为什么避免过敏原仍然是猫过敏管理中最艰巨的挑战之一。暴露于Fel d 1与致敏个体过敏性鼻炎、结膜炎和哮喘的发生和加重相关（6，23，34）。症状可能在直接接触猫后出现，但具有临床相关性的暴露也可源于间接环境污染。对于许多患者，尤其是养猫者，避免策略因人与伴侣动物之间强烈的情感纽带而进一步复杂化，使得与宠物永久分离成为不受欢迎或不切实际的选择。
减少暴露的传统建议主要集中于环境控制措施，包括强化清洁（35）、高效颗粒空气（HEPA）过滤（36）、限制猫进入特定房间或将动物移出住所。尽管这些方法可能不同程度地减少过敏原负荷，但其有效性往往因Fel d 1的持续产生和传播而受限。此外，环境过敏原水平的大幅降低可能需要长期持续的干预。
Fel d 1的持续存在和广泛传播凸显了传统过敏原避免策略的根本局限性：它们仅在过敏原已经产生和扩散后才发挥作用。因此，完全避免过敏原几乎不可能，即使对于不养猫的个体也是如此。这些局限性促进了源头导向干预措施的发展，旨在减少过敏原产生、中和过敏原活性或在广泛环境传播发生之前限制过敏原脱落。这些方法并非试图在事后消除过敏原暴露，而是寻求在过敏原通路的最早阶段进行干预，构成了猫过敏管理中新兴范式的概念基础。
通过猫接种疫苗对Fel d 1进行免疫中和
概念与免疫学原理
在管理猫过敏的新兴源头导向方法中，对猫自身主要过敏原进行疫苗接种代表了一种新兴的源头导向策略，旨在降低猫的致敏潜力。该方法并非在致敏个体暴露后对其进行治疗，而是旨在减少猫本身释放到环境中的生物活性过敏原量。该概念基于针对Fel d 1的主动免疫（37，38），并在图2中加以说明。接种疫苗后，猫产生Fel d 1特异性抗体，在过敏原分泌前或分泌后与其结合。多种机制可能促成由此产生的致敏负荷降低。首先，抗体结合可能减少可用于环境传播的游离Fel d 1量。其次，Fel d 1与疫苗诱导抗体之间形成的免疫复合物可能降低过敏原与致敏个体中过敏原特异性IgE抗体相互作用的能力。因此，疫苗接种有可能同时减少过敏原暴露和致敏活性，尽管这些机制在体内的相对贡献仍不完全清楚。
[图：猫接种 Fel d 1 疫苗后过敏原减少的拟议机制。用 Fe 免疫后]
从免疫学角度来看，针对Fel d 1的疫苗接种代表一种治疗性自身抗原疫苗接种形式，因此必须打破对自身的耐受。类似的策略此前已被探索用于针对内源性靶点，如促性腺激素释放激素GnRH（39，40）、神经生长因子NGF（41–43）、PCSK9（44）和促炎细胞因子（45，46）。多项马的研究也证明了通过疫苗接种刺激抗细胞因子抗体的可行性（47–52）。然而，Fel d 1疫苗接种在这些方法中有一个重要区别。大多数治疗性自身抗原疫苗旨在改变接种个体内的疾病过程，而针对Fel d 1的疫苗接种主要意在通过减少人类的过敏原暴露而使另一物种受益，同时保持猫的健康和福利。在此背景下，任何自身抗原疫苗的关键考虑因素是靶分子的生物学重要性。Fel d 1的生理作用仍不完全清楚，尽管已提出与信息素运输、化学通讯和社会行为相关的功能（53）。这种不确定性既可视为机遇也可视为挑战。一方面，缺乏明确确立的必要功能以及猫之间Fel d 1产生量的显著自然变异表明，部分中和可能具有良好的耐受性。另一方面，目前尚未识别的生物学功能的可能性强调了持续安全监测和长期随访研究的重要性。
低致敏猫疫苗的开发
通过开发低致敏猫疫苗平台，证实了针对 Fel d 1 进行主动免疫的可行性（37, 38）。为克服针对自身蛋白的免疫耐受，将重组 Fel d 1 化学偶联至源自黄瓜花叶病毒的病毒样颗粒（VLPs）。该方法利用 VLPs 高度重复的抗原展示和固有免疫刺激特性，诱导针对原本免疫原性较弱的自身抗原产生强效抗体应答。在初步概念验证研究中（38），接种疫苗可在猫体内诱导强效的抗 Fel d 1 IgG 应答。该疫苗总体耐受良好，观察期内未报告重大疫苗相关不良事件。重要的是，诱导产生的抗体表现出结合天然 Fel d 1 的能力，这提供了证据表明在已发表研究的持续时间内可成功克服免疫耐受。这些发现确立了针对 Fel d 1 进行治疗性疫苗接种的可行性，并为后续评估其对过敏原活性及人类暴露影响的研究奠定了基础。
过敏原减少及临床相关性的证据
后续研究通过评估疫苗诱导的抗 Fel d 1 抗体的功能后果，扩展了这些观察结果（37）。接种疫苗与生物学活性 Fel d 1 水平降低相关，该结论通过 IgE 结合抑制及相关替代试验进行评估（图 2）。这些发现支持核心假设，即接种疫苗可降低 Fel d 1 的致敏潜力，而不一定消除其产生。重要的是，该概念不同于传统的过敏原规避措施。梳理、洗澡或环境清洁旨在在过敏原产生并扩散后将其去除，而接种疫苗则作用于上游，在过敏原广泛释放到环境之前对其进行修饰。因此，接种疫苗有可能提供过敏原负荷的持续降低，同时避免需要频繁重复干预。
尽管有这些令人鼓舞的发现，临床证据仍然有限。迄今为止，尚无随机临床试验证明给猫接种疫苗可在真实世界条件下使其主人过敏性疾病的临床表现获得有意义的改善。相反，研究集中于免疫原性、过敏原测量和致敏活性的替代标志物，而非直接评估过敏个体的临床结局。因此，生物学活性 Fel d 1 的降低在多大程度上转化为真实世界条件下过敏症状、药物使用、哮喘控制或生活质量的持续改善，仍不确定。因此，需要在猫过敏个体中开展设计良好的前瞻性临床研究，以确立该方法的真实临床有效性。总体而言，现有数据提供了令人信服的概念验证，即针对 Fel d 1 的疫苗接种可降低生物学活性过敏原。该策略最终能否转化为对猫过敏个体有意义的临床获益，仍是未来研究的关键问题。
机遇与剩余挑战
低致敏猫研究提供了概念验证，即针对 Fel d 1 的源头导向免疫中和是可行的、具有免疫原性且显然耐受良好（37, 38）。与反复物理去除过敏原的策略相比，接种疫苗可能通过内源性抗体产生提供持续过敏原控制的前景，代表了一种可能与常规环境控制和患者导向治疗互补的方法。此外，接种疫苗可能与其他源头导向干预措施兼容，包括饮食过敏原中和方法、梳理措施和环境控制策略。
然而，若干重要问题仍未得到解答。抗体应答的长期持久性、最佳加强免疫方案以及在过敏个体中减轻症状的真实世界有效性需要进一步研究。同样重要的是继续评估猫的健康与福利，特别是考虑到对 Fel d 1 生理作用的理解尚不完整。尽管迄今未报告重大安全性问题，但仍需要更大规模、随访时间更长的研究来充分描述持续中和 Fel d 1 的后果。除了证明临床疗效和长期安全性外，成功转化为常规实践还将取决于监管批准、兽医和猫主人的接受度、成本效益以及整合到现有过敏管理策略中。因此，未来临床研究应关注以患者为中心的结局，并确定接种疫苗能否使过敏个体在实现持续症状控制的同时保持与猫的接触。如果这些挑战能够得以解决，针对 Fel d 1 的疫苗接种可能成为未来综合管理策略的组成部分，将源头导向的过敏原减少与患者导向治疗相结合。最终，该方法的成功不仅取决于其生物学效力，还取决于在设计良好的前瞻性临床试验中证明对过敏个体具有临床意义的获益。
猫身上过敏原负荷的物理性减少
物理性去除过敏原的理论依据
与旨在减少Fel d 1产生或生物活性的源头导向免疫学方法不同，物理干预旨在去除已沉积在动物被毛和皮肤上的过敏原。由于Fel d 1在理毛过程中从唾液转移至被毛，被毛构成了过敏原持续释放到环境中的重要储库。因此，从被毛上机械性去除过敏原有可能减少环境污染及随后的人体暴露。物理性过敏原减少策略当然具有吸引力，因为它们是非药物性的、相对廉价，且可在不改变猫生物学特性的情况下实施。因此，洗澡、理毛、刷毛以及使用减少过敏原的湿巾常被推荐作为希望与宠物保持接触的猫过敏个体的辅助措施。
洗澡和理毛干预
多项研究探讨了给猫洗澡是否能降低被毛及周围环境中的Fel d 1水平（54）。总体而言，洗澡可导致表面相关过敏原的即时但短暂的减少。Fel d 1通过持续的分泌和理毛行为不断得到补充。研究表明，洗澡后过敏原水平可能在数天甚至数小时内恢复至基线（6, 23, 55），需要频繁重复以维持降低的过敏原负荷。同样，常规理毛和刷毛可去除被毛上含过敏原的毛发、皮屑和表面污染物。虽然这些干预可减少可供环境传播的过敏原量，但其有效性取决于理毛频率、去除的毛发量以及含过敏原材料的后续处理。在实践中，室内理毛可能通过含Fel d 1颗粒的再悬浮和扩散短暂增加空气中过敏原浓度，尤其是在通风不足或缺乏过敏原控制措施的情况下（31）。
洗澡和理毛的一个实际限制是猫的依从性。许多猫在洗澡过程中经历应激，这可能限制长期坚持并引发动物福利方面的考量。因此，尽管这些方法可短暂减少过敏原负荷，但其作为独立干预措施的效用可能有限。
减少过敏原的湿巾和外用产品
最近，市售湿巾、喷雾剂和其他外用制剂已被开发用于减少猫被毛上的过敏原量，而无需大量洗澡（4）。这些产品设计用于物理性去除含过敏原材料或结合并灭活表面相关的Fel d 1。与洗澡相比，湿巾可能提供更好的实用性和宠物主人接受度，允许更频繁地使用且对动物的应激更小。然而，支持其疗效的证据仍然有限，且很少有研究评估除被毛或家庭灰尘中过敏原水平测量之外的临床相关结局。与洗澡一样，过敏原负荷的任何减少都是暂时的，因为Fel d 1的基础产生未受影响。
临床相关性和局限性
从机制角度看，物理性过敏原去除仅针对过敏原传播的最终阶段，并不改变猫的Fel d 1产生。因此，这些干预本质上是反应性的而非预防性的。这将其与新兴的免疫学方法区分开来，后者旨在在生物学活性过敏原到达被毛或环境之前减少其量。
现有文献的一个反复出现的局限性是依赖替代终点，如被毛、沉降灰尘或空气样本中Fel d 1浓度的降低，或此类降低是否转化为临床有意义的改善，例如过敏症状、药物使用或生活质量。此外，过敏原减少的幅度和持续时间在研究之间差异很大，使得比较困难。尽管存在这些局限性，物理性过敏原去除作为多方面过敏原管理策略的一部分可能具有价值。对于尽管已致敏但仍选择养猫的个体，理毛、洗澡和外用减少过敏原产品在与环境干预（如空气过滤、定期清洁和限制进入卧室）相结合时，可能有助于降低累积暴露。然而，当前证据不支持将这些措施作为更有效过敏原减少策略的替代。
遗传和育种方法
Fel d 1产生的自然变异
不同个体猫之间的 Fel d 1 产生量差异很大，这为旨在减少过敏原产生的遗传学和育种方法提供了生物学基础。因此，了解这种自然变异性是制定长期源头导向策略的必要前提。研究表明，动物之间的过敏原水平存在显著差异，且观察到差异与性别、绝育状态、年龄和遗传背景有关。公猫通常比母猫产生更高水平的 Fel d 1（23, 56, 57），而去势与过敏原产生减少相关（57, 58），提示过敏原表达受激素调节。重要的是，个体猫之间的变异幅度往往超过品种间报道的差异。后者凸显了影响 Fel d 1 产生的复杂遗传和环境因素，并提示过敏原性应被视为一种数量性状而非二元性状。
低过敏性猫的概念
“低过敏性”猫品种的存在仍然是过敏个体相当关注的话题。包括斯芬克斯猫、西伯利亚猫、孟加拉猫、巴厘猫、俄罗斯蓝猫、康沃尔卷毛猫和德文卷毛猫在内的几个品种已被营销为产生较低水平过敏原或引起较少过敏症状（59–62）。然而，支持特定品种低过敏性状态的科学证据仍然有限。虽然一些研究报告了选定品种中较低的平均 Fel d 1 水平，但品种之间存在大量重叠，且没有品种被证明始终无过敏原（63）。此外，同一品种内个体动物之间的过敏原产生可能差异很大。因此，“低过敏性猫”一词应谨慎解读。当前证据表明，选择过敏原产生较低的个体猫可能比仅选择品种更有意义。
低过敏性猫的概念二十多年来一直引起相当大的公众兴趣和商业关注。这种兴趣反映了猫过敏个体中大量未满足的需求，他们希望与伴侣动物保持接触的同时尽量减少过敏症状。然而，尽管有许多关于低过敏性品种或低过敏原猫的说法，支持真正低过敏性猫存在的科学证据仍然有限。
遗传选择的未来机遇
猫基因组学的进展为更好地理解 Fel d 1 产生的生物学决定因素创造了新机遇。鉴定与低过敏原表型相关的遗传变异可促进旨在减少过敏原产生同时保留理想品种特征的选择性育种计划。此类方法最终可能被证明比仅依赖品种指定更有效。除传统育种外，新兴的基因组编辑技术提出了直接修饰参与 Fel d 1 产生的基因的可能性。概念验证研究已证明靶向编码 Fel d 1 的 CH1 和 CH2 基因的可行性，凸显了未来开发过敏原产生大幅减少的猫的潜力（59, 62）。
尽管这些概念验证研究前景可观，但在基因组编辑可被视为实用策略之前，仍存在大量技术和转化挑战。当前的基因组编辑技术可能引入意外的脱靶遗传修饰（64, 65），而永久破坏 Fel d 1 表达的长期生物学后果仍不确定（23），需要仔细评估。由于 Fel d 1 的生理功能仍未完全了解，目前不能排除遗传修饰可能影响猫的行为、社会交流、繁殖、皮肤生物学或其他健康方面。此外，基因组编辑伴侣动物的监管批准因国家而异，可能带来重大的法律和社会挑战。伦理考量同样重要，包括关于动物福利、主要为了人类利益而修饰伴侣动物的可接受性，以及将转基因宠物引入社会的更广泛影响等问题。
尽管遗传方法仍处于早期开发阶段，但它们提供了永久性和终身减少过敏原产生的前景。未来研究应侧重于阐明 Fel d 1 的生物学功能、鉴定过敏原表达的遗传决定因素，以及评估培育或改造过敏原潜力降低的猫的安全性、有效性和伦理影响。
新兴概念：从单一干预到综合过敏原管理
Fel d 1 的饮食中和
一种针对过敏原源头控制的新方法是在猫体内中和Fel d 1，以防止其向环境传播。研究最为广泛的例子是将来源于鸡蛋的抗Fel d 1免疫球蛋白Y（IgY）抗体添加到猫粮中（66–68）。摄入后，这些抗体与猫唾液中存在的Fel d 1结合。由于唾液是猫在梳理毛发时沉积于皮毛上的Fel d 1的主要来源，该策略旨在减少随后释放到环境中的生物活性过敏原量。重要的是，该方法并非试图抑制Fel d 1的产生，而是在人类暴露发生之前中和过敏原活性。多项研究报道，在日粮中添加抗Fel d 1 IgY后，皮毛上和环境中的活性Fel d 1水平降低（67, 68）。尽管独立研究已证明其安全性（69），但证明对过敏个体具有直接临床获益的证据仍然有限，且真实条件下的长期有效性需要进一步研究。
被动免疫学方法
疫苗接种和基于日粮抗体的干预措施的成功，凸显了免疫学过过敏原中和策略的更广泛潜力。原则上，被动给予Fel d 1特异性抗体可提供一种替代手段来降低过敏原活性，而无需在猫体内诱导内源性免疫应答。然而，与主动疫苗接种相比，被动免疫面临若干实际挑战。给予的抗体逐渐从循环和组织中清除，需要反复治疗以维持疗效。根据制剂和给药途径的不同，给药间隔可能从数周到数月不等。此外，单克隆或多克隆抗体的大规模生产仍然成本高昂，引发了关于伴侣动物可负担性和长期实施的担忧。
其他挑战包括在Fel d 1产生和分泌部位达到足够的抗体浓度，以及确保对新合成的过敏原的持续中和。因此，尽管被动免疫代表了一种有趣的概念性方法，但与主动疫苗接种策略相比，其实际应用可能有限，后者使猫在免疫后能够持续产生抗Fel d 1抗体。鉴于主动Fel d 1疫苗接种已被证明可行，被动免疫最终作为研究工具的效用可能大于作为常规过敏原管理的实用长期策略。
联合策略与未来临床开发
猫过敏的未来管理不太可能依赖单一干预措施。相反，互补方法的组合可能最大程度地减少过敏原暴露。例如，疫苗接种或日粮过敏原中和可与环境措施和针对性梳理实践相结合，以实现叠加效应。此类综合策略代表了从传统的基于回避的建议向主动管理过敏原产生和传播的转变。随着该领域的成熟，未来研究不仅应关注Fel d 1浓度的降低，还应关注具有临床意义的结局，包括症状控制、生活质量以及过敏个体与伴侣动物保持接触的能力。
猫过敏管理的未来可能不取决于确定单一高效干预措施，而取决于结合互补方法，以减少过敏原产生、过敏原脱落、环境负荷和宿主敏感性。表2显示了上述讨论的针对源头的过敏原减少措施的比较。
Table 2. Comparison of source-directed allergen-reduction strategies. The interventions listed differ substantially in their evidence base, practicality, and implications for animal welfare. Direct comparisons between strategies should therefore be interpreted with caution.
| Strategy | Mechanism | Stage targeted | Expected duration of effect | Advantages | Limitations | Development stage | Levels of evidence |
|---|---|---|---|---|---|---|---|
| Vaccination | Anti-Fel d 1 IgG/IgA | Allergen production and allergen activity | Months to years (with booster vaccination) | Long-lasting effect; source-directed; potentially reduces biologically active allergen before environmental dissemination | Limited clinical outcome data; requires vaccination and booster schedule; long-term consequences of Fel d 1 neutralization remain incompletely understood | Pre-clinical, veterinary field studies | Moderate |
| Dietary IgY | Anti-Fel d 1 IgY | Allergen activity and shedding | Months (continuous feeding required) | Non-invasive; easy implementation; compatible with other interventions | Requires continuous feeding; limited human clinical outcome data; ongoing cost | Commercially available, translational studies | Moderate |
| Grooming, wipes | Physical Fel d 1 removal | Allergen on fur | Days to weeks | Simple; non-pharmacological; can be combined with other measures | Transient effect; repeated application required; variable cat acceptance | Established | Low-moderate |
| Bathing | Physical Fel d 1 removal | Allergen on fur | Days to weeks | Immediate reduction of surface allergen burden | Short-lived effect; poor compliance in many cats; potential stress for the animal | Established | Low-moderate |
| Environmental control | Removal of allergen from indoor environment (e.g., cleaning, HEPA filtration) | Environmental allergen burden | Continuous while maintained | Applicable regardless of allergen source; may complement source-directed interventions | Does not reduce allergen production; labour-intensive; difficult to achieve complete allergen removal | Partly established | Moderate |
| Breeding, genetics | Reduced Fel d 1 production | Allergen production | Lifelong | Potentially permanent reduction in allergen production | Limited evidence; substantial variability between individuals; ethical, welfare, and biological considerations | Experimental | Low |
结论与未来展望
猫过敏仍是全球过敏性鼻炎和哮喘的主要原因，由于Fel d 1的广泛分布以及人与伴侣动物之间的紧密纽带，过敏原回避往往具有挑战性。传统管理主要侧重于通过药物治疗、AIT和环境控制措施治疗过敏个体，而新兴的源头导向方法则寻求从源头减少过敏原暴露。
诱导抗Fel d 1抗体的疫苗接种策略、中和过敏原活性的饮食方法、减少皮毛过敏原负荷的物理方法以及旨在降低过敏原产生的遗传学方法，共同代表了从管理过敏原暴露后果向从源头控制过敏原产生和传播的范式转变。这些干预措施不应被视为患者导向治疗的替代方案，而应视为综合管理策略的补充组成部分。未来宠物过敏的管理可能将源头导向干预与改进的患者导向治疗（包括更安全、更有效的AIT形式）相结合，以减少过敏原暴露和宿主敏感性。
未来发展还应考虑宠物主人及其家庭的视角，伴侣动物为其提供重要的情感、心理和社会益处。同样重要的是动物福利的考量。与大多数兽医干预措施不同，许多源头导向的过敏原控制策略主要设计为惠及过敏个体而非动物本身。因此，其开发和实施不仅应以疗效为指导，还应仔细评估其对猫健康、行为和福祉的影响。安全、微创且与正常猫生理和行为相容的干预措施可能在兽医、宠物主人和整个社会中获得更广泛的接受。在某些情况下，源头导向干预可能通过减少因过敏相关问题而放弃宠物或安乐死的需要，最终惠及人类和动物双方。
最终，宠物过敏管理的目标不一定是完全消除过敏原暴露，而是使过敏个体和伴侣动物能够在疾病负担最小的情况下共存，同时保持生活质量、人与动物纽带和动物福利。源头导向过敏原控制的持续进展，连同患者导向治疗的改进，可能有助于将这一目标转化为现实。最后，未来猫过敏的管理可能需要将源头导向过敏原减少与患者导向治疗相结合，同时考虑更广泛的生物学因素，包括上皮屏障功能和环境对过敏性疾病的影响。
资助声明
作者声明本研究及/或其发表获得了财务支持。PJ目前获得LEO基金会（LF-OC-26-002695）的资助，MP获得苏黎世大学青年学者促进基金（FAN）的资助，用于临床前过敏研究。LS获得Bruno Bloch Stiftung的资助，用于人类过敏原免疫治疗研究。
脚注
[内容请查看原文]
作者贡献
CG：可视化，写作——审阅与编辑。AL：写作——审阅与编辑。LS：写作——审阅与编辑。MP：写作——审阅与编辑。TK：写作——审阅与编辑，资源，资金获取。PJ：概念构思，监督，可视化，写作——审阅与编辑，资源，写作——初稿，资金获取。
利益冲突
TK被列为猫抗Fel d 1疫苗的发明人，并且是Saiba Biotechnology AG和Evax AG的股东，这两家公司均开发动物疫苗。PJ从Bencard AG和Allergy Therapeutics Ltd获得了财务研究资助和差旅补助，这两家公司均开发和销售过敏治疗产品。
其余作者声明，本研究是在不存在任何可能被解释为潜在利益冲突的商业或财务关系的情况下进行的。
生成式人工智能声明
作者声明在本稿件的创作中使用了生成式人工智能。ChatGPT（GPT-5.5，OpenAI，https://chatgpt.com）被用于协助图2的概念开发和图形布局。此外，文本使用同一工具进行了简化和修订。所有科学内容及解释均由作者创建、验证并批准。
本文图表旁提供的任何替代文本（alt text）均由Frontiers在人工智能支持下生成，并已做出合理努力以确保准确性，包括在可能情况下由作者进行审阅。如您发现任何问题，请联系我们。
出版商注
本文中表达的所有主张仅代表作者本人，不一定代表其所属组织，也不一定代表出版商、编辑和审稿人的观点。本文中可能评估的任何产品或其制造商可能提出的任何主张，均不受出版商的保证或认可。
参考文献
[内容请查看原文]
查看英文原文▾
Introduction: a paradigm shift in cat allergy management
Pet animals play an increasingly important role in modern society (1–3). Dogs and cats are among the most owned pets worldwide and provide substantial emotional, psychological, and social benefits to their owners (4–6). However, exposure to pet allergens is also a major cause of allergic disease, affecting a significant proportion of the population (4), and contributing to the global burden of allergic rhinitis and asthma (7). As rates of pet ownership continue to rise (8), the number of individuals exposed to pet allergens is likely to increase accordingly.
Pet allergy is associated with a broad spectrum of clinical manifestations, ranging from rhinoconjunctivitis and skin symptoms to asthma and severe exacerbations in sensitised individuals (7, 9). Cat and dog allergens are among the most important indoor allergens, and sensitisation to furry animals has been associated with increased asthma prevalence, greater disease severity, and impaired quality of life (4, 10). Importantly, pet allergens are not confined to pet-owning households but are widely distributed in public and private indoor environments (11), making complete avoidance difficult even for individuals who do not own pets (12, 13).
The development and severity of pet allergy are influenced by multiple interacting factors, including allergen exposure, epithelial barrier integrity, host immune responses, and environmental determinants. Rather than representing a single disease mechanism, allergic sensitization results from complex interactions between the animal, the environment, and the allergic individual. Recent research have highlighted the importance of these mechanisms and emphasized the need for integrated approaches that address both allergen exposure and host susceptibility (14, 15). Within this broader framework, source-directed strategies aim to reduce allergen burden at its origin and complement established patient-directed interventions.
Current management relies largely on allergen avoidance, pharmacotherapy and allergen immunotherapy (AIT), each with important limitations. Avoidance is often impractical because pet allergens are ubiquitous, and many patients are unwilling to part with their companion animals. Pharmacological treatments can effectively control symptoms but do not modify the underlying allergic disease. Although AIT remains the only disease-modifying treatment currently available, its role in pet allergy remains controversial (5, 16). Compared with pollen or venom immunotherapy, the evidence base supporting cat and dog AIT is more limited, treatment responses appear more variable, and safety concerns may arise in patients with concomitant asthma (16–19) Important questions remain regarding the efficacy, safety, patient selection, and optimal implementation of pet AIT (5). Consequently, there remains a need for both improved source-directed allergen reduction strategies and safer, more effective patient-directed immunomodulatory therapies. Approaches for safer pet AIT have reported with the production of hypoallergenic allergen derivates that cause less allergic adverse events when applied in conventional subcutaneous immunotherapy (SCIT) (20) or by using intralymphatic immunotherapy (ILIT) that requires less injections with lower allergen doses (21).
The challenges associated with pet allergy are further complicated by the strong emotional bond between humans and their pets. For many individuals and families, pet ownership provides substantial benefits that make pet removal undesirable or unacceptable. Thus, the goal of allergy management extends beyond symptom control alone and increasingly encompasses the preservation of the human-animal relationship, while maintaining the health and well-being of both the patient and the animal.
Historically, efforts to manage pet allergy have focused almost exclusively on the allergic individual. In recent years, however, a new paradigm has emerged in which the animal itself becomes the target of intervention (4). Advances in vaccination, dietary allergen neutralisation, grooming strategies, and genetic approaches have created opportunities to reduce allergen production, activity, and dissemination before exposure occurs. These source-directed approaches complement conventional patient-directed therapies and may ultimately enable more effective and sustainable management of pet allergy. Below, we discuss such current and emerging strategies, which all aim at reducing the allergenic potential of furry animals. With a particular focus on cats, we examine interventions targeting allergen production, allergen activity, and allergen shedding, and consider how these approaches may be integrated with established patient-directed therapies to reduce disease burden, improve quality of life, preserve the human–animal bond, and ensure animal welfare. Figure 1 and Table 1 illustrate and list overviews of the integrated management strategies for cat allergy.
[图：Conceptual overview of integrated management strategies for cat allergy. Fel d 1 is produced by the cat and subsequently]
Table 1. Framework for integrated management of cat allergy.
| Stage | Example intervention | Primary objective |
|---|---|---|
| Allergen production | Vaccination, genetic selection | Reduce allergen generation and biologically active allergen |
| Allergen activity | Vaccination-induced antibodies, dietary anti-Fel d 1 IgY | Reduce biologically active allergen |
| Allergen on fur | Grooming, wipes, sprays, bathing | Reduce surface allergen burden |
| Environmental burden | Cleaning, HEPA filtration | Reduce environmental exposure |
| Human immune response | Allergen immunotherapy, biologics, pharmacotherapy | Increase tolerance and control symptoms |
Fel d 1 as the primary target
Biology of Fel d 1
Fel d 1 is the major cat allergen and the principal cause of sensitisation and allergic symptoms in cat-allergic individuals (22, 23). Nearly 95% of cat-allergic patients have specific IgE antibodies directed against Fel d 1, making it the dominant target of the allergic immune response. Unlike many other mammalian allergens, Fel d 1 is produced almost exclusively by cats and therefore represents a highly specific marker of cat allergen exposure. Structurally, Fel d 1 is a secretoglobin consisting of two distinct polypeptide chains linked by three disulfide bonds to form a heterodimer (24–26) Two heterodimers can further associate through non-covalent interactions to form a tetrameric complex (25, 27). Although its precise biological function remains uncertain, Fel d 1 has been proposed to contribute to pheromone transport and chemical communication between cats. Its localisation in sebaceous, salivary, and anal glands (28) suggests a role in the production or dissemination of chemical signals involved in territorial and social behaviours. During grooming, saliva containing Fel d 1 is deposited onto the fur and skin, from where the allergen becomes airborne and is continuously released into the environment.
Why target Fel d 1?
Several characteristics make Fel d 1 an attractive target for source-directed interventions. First, it is the dominant cat allergen recognised by the vast majority of cat-allergic individuals (29). Seven other and minor allergens (Fel d 2–8) have been described (4, 22, 30). Reducing exposure to Fel d 1 is therefore expected to benefit a large proportion of patients, whereas targeting minor allergens would likely have a more limited impact. Second, production of Fel d 1 is almost exclusively by the cat and the allergen is released into the environment before human exposure occurs. This creates a unique opportunity to intervene at the source rather than solely treating the downstream allergic response in sensitised individuals. Current management strategies—including allergen avoidance, pharmacotherapy, and AIT—are directed at the patient and do not modify allergen production by the animal. In contrast, interventions targeting Fel d 1 production, activity, or shedding have the potential to reduce allergen exposure for all individuals interacting with the cat. Third, Fel d 1 possesses several characteristics that make it amenable to source-directed interventions. Because the allergen is produced by a limited number of tissues, deposited on the fur during grooming, and subsequently disseminated into the environment, multiple opportunities exist to reduce its production, neutralise its biological activity, or limit its environmental accumulation. These characteristics have stimulated the development of diverse strategies aimed at lowering exposure to biologically active Fel d 1.
Taken together, the central role of Fel d 1 in cat allergy, its cat-specific origin, and its accessibility to source-directed interventions make Fel d 1 the logical focal point for emerging approaches to allergy management. Beyond treating the consequences of allergen exposure, the strategies also aim to reduce exposure at its source, representing a significant potent in the management of cat allergy.
Environmental exposure and clinical relevance of Fel d 1
The clinical significance of Fel d 1 is determined not only by its potent allergenicity but also by its remarkable capacity for environmental dissemination and persistence. Following deposition onto the fur, Fel d 1 is continuously released on hair, dander, and microscopic airborne particles that readily disperse throughout indoor environments and adhere to clothing, furniture, carpets, and other surfaces. Consequently, Fel d 1 may remain detectable for months after a cat has been removed from the home (12, 13, 31, 32). In addition to direct exposure in cat-owning households, passive transport of allergen on clothing and personal belongings contributes to the widespread distribution of Fel d 1. Measurable allergen levels have been detected in schools, workplaces, hotels, public transportation, and other environments where cats have never been present (12, 33). Consequently, complete avoidance of cat allergen exposure is often difficult to achieve, even for individuals who do not own cats themselves.
This widespread dissemination explains why allergen avoidance remains one of the greatest challenges in cat allergy management. Exposure to Fel d 1 has been associated with the development and exacerbation of allergic rhinitis, conjunctivitis, and asthma in sensitised individuals (6, 23, 34). Symptoms may occur following direct contact with cats, but clinically relevant exposure can also result from indirect environmental contamination. For many patients, particularly cat owners, avoidance strategies are further complicated by the strong emotional bond between humans and their companion animals, making permanent separation from the pet an undesirable or impractical option.
Traditional recommendations for reducing exposure have focused primarily on environmental control measures, including intensive cleaning (35), high-efficiency particulate air (HEPA) filtration (36), restricting cat access to specific rooms, or removal of the animal from the home. Although these approaches may reduce allergen burden to varying degrees, their effectiveness is often limited by the continuous production and dissemination of Fel d 1. Furthermore, substantial reductions in environmental allergen levels may require prolonged and sustained interventions.
The persistence and widespread dissemination of Fel d 1 highlight a fundamental limitation of conventional allergen avoidance strategies: they act only after the allergen has already been produced and dispersed. As a result, complete allergen avoidance is virtually impossible, even for individuals who do not own cats. These limitations have stimulated the development of source-directed interventions that aim to reduce allergen production, neutralise allergen activity, or limit allergen shedding before widespread environmental dissemination occurs. Rather than attempting to eliminate allergen exposure after the fact, these approaches seek to intervene at the earliest stages of the allergen pathway, forming the conceptual basis of an emerging paradigm in cat allergy management.
Immunological neutralisation of Fel d 1 through cat vaccination
Concept and immunological rationale
Among the emerging source-directed approaches for managing cat allergy, vaccination of cats against their own major allergen represents an emerging source-directed strategy that aims to reduce the allergenic potential of cats. Rather than treating allergic individuals after exposure has occurred, this approach aims to reduce the amount of biologically active allergen released into the environment by the cat itself. The concept is based on active immunisation against Fel d 1 (37, 38) and illustrated in Figure 2. Following vaccination, cats develop Fel d 1-specific antibodies that bind the allergen before or after secretion. Several mechanisms may contribute to the resulting reduction in allergenic burden. First, antibody binding may reduce the amount of free Fel d 1 available for environmental dissemination. Second, immune complexes formed between Fel d 1 and vaccine-induced antibodies may reduce the ability of the allergen to interact with allergen-specific IgE antibodies in sensitised individuals. Consequently, vaccination has the potential to reduce both allergen exposure and allergenic activity, although the relative contribution of these mechanisms in vivo remains incompletely understood.
[图：Proposed mechanism of allergen reduction following vaccination of cats against Fel d 1. Following immunisation with a Fe]
From an immunological perspective, vaccination against Fel d 1 represents a form of therapeutic self-antigen vaccination, hence, the tolerance to self must be broken. Similar strategies have previously been explored against endogenous targets such as gonadotropin-releasing hormone GnRH (39, 40), nerve growth factor NGF (41–43), PCSK9 (44), and pro-inflammatory cytokines (45, 46). Several studies in horses also have demonstrated the feasibility of stimulating anti-cytokine antibodies through vaccination (47–52) However, Fel d 1 vaccination differs from these approaches in an important respect. Whereas most therapeutic self-antigen vaccines aim to modify disease processes within the vaccinated individual, vaccination against Fel d 1 is primarily intended to benefit another species by reducing allergen exposure in humans while preserving the health and welfare of the cat. In this context, a critical consideration for any self-antigen vaccine is the biological importance of the target molecule. The physiological role of Fel d 1 remains incompletely understood, although functions related to pheromone transport, chemical communication, and social behaviour have been proposed (53). This uncertainty may be viewed both as an opportunity and a challenge. On one hand, the absence of a clearly established essential function and the substantial natural variation in Fel d 1 production among cats suggest that partial neutralisation may be well tolerated. On the other hand, the possibility of currently unrecognised biological functions underscores the importance of continued safety monitoring and long-term follow-up studies.
Development of a hypocat vaccine
The feasibility of active immunisation against Fel d 1 was demonstrated through the development of a hypocat vaccine platform (37, 38). To overcome immunological tolerance against the self-protein, recombinant Fel d 1 was chemically linked to virus-like particles (VLPs) derived from cucumber mosaic virus. This approach exploits the highly repetitive antigen display and intrinsic immunostimulatory properties of VLPs to induce robust antibody responses against otherwise poorly immunogenic self-antigens. In the initial proof-of-concept study (38), vaccination induced robust anti-Fel d 1 IgG responses in cats. The vaccine was generally well tolerated, and no major vaccine-related adverse effects were reported during the observation period. Importantly, the induced antibodies demonstrated the capacity to bind native Fel d 1, providing evidence that immunological tolerance could be successfully overcome within the duration of the published studies. These findings established the feasibility of therapeutic vaccination against Fel d 1 and provided the foundation for subsequent investigations assessing its impact on allergen activity and human exposure.
Evidence for allergen reduction and clinical relevance
Subsequent studies extended these observations by evaluating the functional consequences of vaccine-induced anti-Fel d 1 antibodies (37). Vaccination was associated with reduced levels of biologically active Fel d 1 as assessed by inhibition of IgE binding and related surrogate assays (Figure 2). These findings support the central hypothesis that vaccination can reduce the allergenic potential of Fel d 1 without necessarily eliminating its production. Importantly, the concept differs from conventional allergen avoidance measures. Whereas grooming, bathing, or environmental cleaning aim to remove allergen after it has been produced and disseminated, vaccination acts upstream by modifying the allergen before widespread environmental release occurs. As a result, vaccination has the potential to provide sustained reductions in allergen burden while avoiding the need for frequent repetitive interventions.
Despite these encouraging findings, clinical evidence remains limited. To date, no randomised clinical trials have demonstrated that vaccination of cats leads to clinically meaningful improvements in allergic disease in their owners under real-world conditions. In contrast, studies focused on immunogenicity, allergen measurements, and surrogate markers of allergenic activity rather than direct assessment of clinical outcomes in allergic individuals. Consequently, it remains uncertain to what extent reductions in biologically active Fel d 1 translate into sustained improvements in allergic symptoms, medication use, asthma control, or quality of life under real-world conditions. Well-designed prospective clinical studies in cat-allergic individuals are therefore needed to establish the true clinical effectiveness of this approach. Collectively, the available data provide compelling proof-of-concept that vaccination against Fel d 1 can reduce biologically active allergen. Whether this strategy ultimately translates into meaningful clinical benefit for cat-allergic individuals remains the key question for future research.
Opportunities and remaining challenges
The hypocat studies provide proof-of-concept that source-directed immunological neutralisation of Fel d 1 is feasible, immunogenic, and apparently well tolerated (37, 38). Compared with repeated physical allergen-removal strategies, vaccination may offer the prospect of sustained allergen control through endogenous antibody production representing a potentially complementary approach to conventional environmental control and patient-directed therapies. Furthermore, vaccination is potentially compatible with other source-directed interventions, including dietary allergen-neutralisation approaches, grooming measures, and environmental control strategies.
Several important questions nevertheless remain unanswered. Long-term durability of antibody responses, optimal booster schedules, and real-world effectiveness in reducing symptoms among allergic individuals require further study. Equally important is the continued evaluation of feline health and welfare, particularly given the incomplete understanding of the physiological role of Fel d 1. Although no major safety concerns have been reported to date, larger studies with longer follow-up will be necessary to fully characterise the consequences of sustained Fel d 1 neutralisation. Beyond demonstrating clinical efficacy and long-term safety, successful translation into routine practice will also depend on regulatory approval, acceptance by veterinarians and cat owners, cost-effectiveness, and integration into existing allergy management strategies. Future clinical studies should therefore focus on patient-centred outcomes and determine whether vaccination enables allergic individuals to maintain contact with their cats while achieving sustained symptom control. If these challenges can be addressed, vaccination against Fel d 1 could become one component of future integrated management strategies that combine source-directed allergen reduction with patient-directed therapies. Ultimately, the success of this approach will depend not only on its biological efficacy but also on demonstrating clinically meaningful benefit for allergic individuals in well-designed prospective clinical trials.
Physical reduction of allergen load on the cat
Rationale for physical allergen removal
Unlike source-directed immunological approaches that seek to reduce the production or biological activity of Fel d 1, physical interventions aim to remove allergen after it has been deposited onto the fur and skin of the animal. Because Fel d 1 is transferred from saliva to the coat during grooming, the fur represents an important reservoir from which allergen is continuously released into the environment. Mechanical removal of allergen from the coat therefore has the potential to reduce environmental contamination and subsequent human exposure. Physical allergen reduction strategies are of course attractive because they are non-pharmacological, relatively inexpensive, and can be implemented wihout altering the cat's biology. Consequently, bathing, grooming, brushing, and the use of allergen-reducing wipes have frequently been recommended as adjunctive measures for cat-allergic individuals wishing to maintain contact with their pets.
Bathing and grooming interventions
Several studies have investigated whether washing cats can reduce Fel d 1 levels on the fur and in the surroundings (54). In general, bathing results in an immediate but transient reduction of surface-associated allergen. Fel d 1 is continuously replenished through ongoing secretion and grooming behaviour. Studies have demonstrated that allergen levels may return to baseline within days or even hours following bathing (6, 23, 55), necessitating frequent repetition to maintain reduced allergen loads. Similarly, routine grooming and brushing may remove allergen-containing hair, dander, and surface contaminants from the coat. While these interventions can reduce the amount of allergen available for environmental dissemination, their effectiveness depends on grooming frequency, the amount of hair removed, and the subsequent handling of allergen-containing material. In practice, grooming performed indoors may transiently increase airborne allergen concentrations through resuspension and dispersal of Fel d 1-containing particles, particularly in the absence of adequate ventilation or allergen control measures (31).
A practical limitation of both bathing and grooming is cat compliance. Many cats experience stress during bathing procedures, which may limit long-term adherence and raise animal welfare considerations. Consequently, although these approaches can transiently reduce allergen burden, their utility as stand-alone interventions is likely limited.
Allergen-reducing wipes and topical products
More recently, commercially available wipes, sprays, and other topical formulations have been developed to reduce amount of allergen on the cat's coat without the need for extensive bathing (4). These products are designed either to physically remove allergen-containing material or to bind and inactivate surface-associated Fel d 1. Compared with bathing, wipes may offer improved practicality and owner acceptance, allowing more frequent application with less stress to the animal. However, evidence supporting their efficacy remains limited, and few studies have evaluated clinically relevant outcomes beyond measurements of allergen levels on the fur or in household dust. As with bathing, any reduction in allergen burden is temporary because the underlying production of Fel d 1 remains unaffected.
Clinical relevance and limitations
From a mechanistic perspective, physical allergen removal addresses only the final stage of allergen dissemination and does not change the cat's Fel d 1 production. Consequently, these interventions are inherently reactive rather than preventive. This distinguishes them from emerging immunological approaches that seek to reduce the amount of biologically active allergen before it reaches the fur or environment.
A recurring limitation of the available literature is the reliance on surrogate endpoints such as reductions in Fel d 1 concentrations on fur, in settled dust, or in airborne samples, or whether such reductions translate into clinically meaningful improvements, e.g., allergy symptoms, medication use, or quality of life. Furthermore, the magnitude and duration of allergen reduction vary considerably between studies, making comparisons difficult. Despite these limitations, physical allergen removal may have value as part of a multifaceted allergen-management strategy. For individuals who choose to keep a cat despite sensitisation, grooming, bathing, and topical allergen-reducing products may contribute to lowering cumulative exposure when combined with environmental interventions such as air filtration, regular cleaning, and restricted access to bedrooms. However, current evidence does not support these measures as a substitute for more effective allergen-reduction strategies.
Genetic and breeding approaches
Natural variation in Fel d 1 production
Fel d 1 production varies considerably between individual cats, providing the biological basis for genetic and breeding approaches aimed at reducing allergen production. Understanding this natural variability is therefore an essential prerequisite for developing long-term source-directed strategies. Studies have demonstrated substantial differences in allergen levels between animals, with variation observed according to sex, neutering status, age, and genetic background. Male cats generally produce higher levels of Fel d 1 than females (23, 56, 57), while castration is associated with reduced allergen production (57, 58), suggesting hormonal regulation of allergen expression. Importantly, the magnitude of variation between individual cats often exceeds the differences reported between breeds. The latter highlights the complex genetic and environmental factors that contribute to Fel d 1 production and suggests that allergenicity should be considered a quantitative rather than binary trait.
The concept of hypoallergenic cats
The existence of “hypoallergenic” cat breeds remains a topic of considerable interest among allergic individuals. Several breeds, including Sphynx, Siberian, Bengal, Balinese, Russian Blue, Cornish Rex, and Devon Rex have been marketed as producing lower levels of allergen or causing fewer allergic symptoms (59–62) However, scientific evidence supporting the hypoallergenic status of specific breeds remains limited. While some studies have reported lower average Fel d 1 levels in selected breeds, substantial overlap exists between breeds, and no breed has been shown to be consistently allergen-free (63). Furthermore, allergen production may vary considerably among individual animals within the same breed. Consequently, the term “hypoallergenic cat” should be interpreted with caution. Current evidence suggests that selecting individual cats with lower allergen production may be more relevant than breed selection alone.
The concept of hypoallergenic cats has attracted considerable public interest and commercial attention for more than two decades. This interest reflects the substantial unmet need among cat-allergic individuals who wish to maintain contact with companion animals while minimising allergic symptoms. However, despite numerous claims regarding hypoallergenic breeds or low-allergen cats, scientific evidence supporting the existence of truly hypoallergenic cats remains limited.
Future opportunities for genetic selection
Advances in feline genomics are creating new opportunities to better understand the biological determinants of Fel d 1 production. Identification of genetic variants associated with low-allergen phenotypes could facilitate selective breeding programs aimed at reducing allergen production while preserving desirable breed characteristics. Such approaches may ultimately prove more effective than relying on breed designation alone. Beyond conventional breeding, emerging genome-editing technologies have raised the possibility of directly modifying genes involved in Fel d 1 production. Proof-of-concept studies have demonstrated the feasibility of targeting the CH1 and CH2 genes encoding Fel d 1, highlighting the potential for future development of cats with substantially reduced allergen production (59, 62).
Despite these promising proof-of-concept studies, substantial technical and translational challenges remain before genome editing could be considered a practical strategy. Current genome-editing technologies may introduce unintended off-target genetic modifications (64, 65), and the long-term biological consequences of permanently disrupting Fel d 1 expression remain uncertain (23) and warrant careful evaluation. Because the physiological functions of Fel d 1 remain incompletely understood, it cannot yet be excluded that genetic modification could affect feline behaviour, social communication, reproduction, skin biology, or other aspects of health. Furthermore, regulatory approval of genome-edited companion animals differs substantially between countries and is likely to present significant legal and societal challenges. Ethical considerations are equally important, including questions regarding animal welfare, the acceptability of modifying companion animals primarily to benefit humans, and the broader implications of introducing genetically modified pets into society.
Although genetic approaches remain at an early stage of development, they offer the prospect of permanent and lifelong reduction of allergen production. Future research should focus on elucidating the biological function of Fel d 1, identifying genetic determinants of allergen expression, and evaluating the safety, efficacy, and ethical implications of breeding or engineering cats with reduced allergenic potential.
Emerging concepts: from single interventions to integrated allergen management
Dietary neutralisation of Fel d 1
A novel approach to source-directed allergen control involves the neutralisation of Fel d 1 within the cat before environmental dissemination occurs. The most extensively studied example is the incorporation of anti-Fel d 1 immunoglobulin Y (IgY) antibodies derived from chicken eggs into cat food (66–68) Following ingestion, these antibodies bind Fel d 1 present in feline saliva. Because saliva is the primary source of Fel d 1 deposited onto the fur during grooming, this strategy aims to reduce the amount of biologically active allergen subsequently released into the environment. Importantly, the approach does not seek to suppress Fel d 1 production but rather to neutralise allergen activity before human exposure occurs. Several studies have reported reductions in active Fel d 1 levels on the fur and in the environment following dietary supplementation with anti-Fel d 1 IgY (67, 68). While safety has been shown in independent studies (69), evidence demonstrating direct clinical benefit in allergic individuals remains limited, and long-term effectiveness under real-world conditions requires further investigation.
Passive immunological approaches
The success of vaccination and dietary antibody-based interventions highlights the broader potential of immunological allergen-neutralisation strategies. In principle, passive administration of Fel d 1-specific antibodies could provide an alternative means of reducing allergen activity without requiring the induction of an endogenous immune response in the cat. However, compared with active vaccination, passive immunization faces several practical challenges. Administered antibodies are gradually cleared from circulation and tissues, necessitating repeated treatment to maintain efficacy. Depending on the formulation and route of administration, dosing intervals would likely range from weeks to months. Furthermore, the large-scale production of monoclonal or polyclonal antibodies remains costly, raising concerns regarding affordability and long-term implementation in companion animals.
Additional challenges include achieving sufficient antibody concentrations at the sites of Fel d 1 production and secretion, as well as ensuring sustained neutralisation of newly synthesised allergen. Consequently, although passive immunisation represents an intriguing conceptual approach, its practical application may be limited compared with active vaccination strategies that enable the cat to continuously generate anti-Fel d 1 antibodies following immunisation. Given the demonstrated feasibility of active Fel d 1 vaccination, passive immunisation may ultimately find greater utility as a research tool than as a practical long-term strategy for routine allergen management.
Combination strategies and future clinical development
Future management of cat allergy is unlikely to rely on a single intervention. Instead, combinations of complementary approaches may provide the greatest reduction in allergen exposure. For example, vaccination or dietary allergen neutralisation could be combined with environmental measures and targeted grooming practices to achieve additive effects. Such integrated strategies represent a shift away from traditional avoidance-based recommendations and toward proactive management of allergen production and dissemination. As the field matures, future studies should focus not only on reductions in Fel d 1 concentrations but also on clinically meaningful outcomes, including symptom control, quality of life, and the ability of allergic individuals to maintain contact with companion animals.
The future of cat allergy management may not depend on identifying a single highly effective intervention but rather on combining complementary approaches that reduce allergen production, allergen shedding, environmental burden, and host sensitivity. Table 2 shows a comparison of the above-discussed, source-directed allergen-reduction measures.
Table 2. Comparison of source-directed allergen-reduction strategies. The interventions listed differ substantially in their evidence base, practicality, and implications for animal welfare. Direct comparisons between strategies should therefore be interpreted with caution.
| Strategy | Mechanism | Stage targeted | Expected duration of effect | Advantages | Limitations | Development stage | Levels of evidence |
|---|---|---|---|---|---|---|---|
| Vaccination | Anti-Fel d 1 IgG/IgA | Allergen production and allergen activity | Months to years (with booster vaccination) | Long-lasting effect; source-directed; potentially reduces biologically active allergen before environmental dissemination | Limited clinical outcome data; requires vaccination and booster schedule; long-term consequences of Fel d 1 neutralization remain incompletely understood | Pre-clinical, veterinary field studies | Moderate |
| Dietary IgY | Anti-Fel d 1 IgY | Allergen activity and shedding | Months (continuous feeding required) | Non-invasive; easy implementation; compatible with other interventions | Requires continuous feeding; limited human clinical outcome data; ongoing cost | Commercially available, translational studies | Moderate |
| Grooming, wipes | Physical Fel d 1 removal | Allergen on fur | Days to weeks | Simple; non-pharmacological; can be combined with other measures | Transient effect; repeated application required; variable cat acceptance | Established | Low-moderate |
| Bathing | Physical Fel d 1 removal | Allergen on fur | Days to weeks | Immediate reduction of surface allergen burden | Short-lived effect; poor compliance in many cats; potential stress for the animal | Established | Low-moderate |
| Environmental control | Removal of allergen from indoor environment (e.g., cleaning, HEPA filtration) | Environmental allergen burden | Continuous while maintained | Applicable regardless of allergen source; may complement source-directed interventions | Does not reduce allergen production; labour-intensive; difficult to achieve complete allergen removal | Partly established | Moderate |
| Breeding, genetics | Reduced Fel d 1 production | Allergen production | Lifelong | Potentially permanent reduction in allergen production | Limited evidence; substantial variability between individuals; ethical, welfare, and biological considerations | Experimental | Low |
Conclusions and future perspectives
Cat allergy remains a major cause of allergic rhinitis and asthma worldwide, and allergen avoidance is often challenging because of the ubiquitous distribution of Fel d 1 and the strong bond between humans and their companion animals. While traditional management has focused primarily on treating allergic individuals through pharmacotherapy, AIT, and environmental control measures, emerging source-directed approaches seek to reduce allergen exposure at its origin.
Vaccination strategies that induce anti-Fel d 1 antibodies, dietary approaches that neutralise allergen activity, physical methods that reduce allergen burden on the coat, and genetic approaches aimed at lowering allergen production collectively represent a paradigm shift from managing the consequences of allergen exposure to controlling allergen production and dissemination at its source. These interventions should not be viewed as alternatives to patient-directed therapies but as complementary components of an integrated management strategy. Future management of pet allergy will likely combine source-directed interventions with improved patient-directed therapies, including safer and more effective forms of AIT, to reduce both allergen exposure and host sensitivity.
Future developments should also consider the perspectives of pet owners and their families, for whom companion animals provide important emotional, psychological, and social benefits. Equally important are considerations of animal welfare. Unlike most veterinary interventions, many source-directed allergen-control strategies are designed primarily to benefit allergic individuals rather than the animals themselves. Consequently, their development and implementation should be guided not only by efficacy but also by careful evaluation of their impact on feline health, behaviour, and well-being. Interventions that are safe, minimally invasive, and compatible with normal feline physiology and behaviour are likely to achieve greater acceptance among veterinarians, pet owners, and society at large. In some cases, source-directed interventions may ultimately benefit both humans and animals by reducing the need for pet relinquishment or euthanasia due to allergy-related concerns.
Ultimately, the goal of pet allergy management is not necessarily the complete elimination of allergen exposure but rather enabling allergic individuals and companion animals to coexist with minimal disease burden while preserving quality of life, the human-animal bond, and animal welfare. Continued advances in source-directed allergen control, together with improvements in patient-directed therapies, may help transform this goal into a practical reality. Finally, future management of cat allergy will likely require integration of source-directed allergen reduction with patient-directed therapies while also considering broader biological factors, including epithelial barrier function and environmental influences on allergic disease.
Funding Statement
The author(s) declared that financial support was received for this work and/or its publication. PJ is currently receiving funding from LEO foundation (LF-OC-26-002695) and MP receiving funding from UZH Fund for the Advancement of Young Academics (FAN) for pre-clinical allergy research. LS is receiving funding from Bruno Bloch Stiftung for research on allergen immunotherapy in humans.
Footnotes
[内容请查看原文]
Author contributions
CG: Visualization, Writing – review & editing. AL: Writing – review & editing. LS: Writing – review & editing. MP: Writing – review & editing. TK: Writing – review & editing, Resources, Funding acquisition. PJ: Conceptualization, Supervision, Visualization, Writing – review & editing, Resources, Writing – original draft, Funding acquisition.
Conflict of interest
TK is mentioned as inventor of anti-Fel d 1 vaccines for cats and stockholder in Saiba Biotechnology AG and in Evax AG which both develop vaccines for animals. PJ has received financial research contributions and travel grants from Bencard AG and Allergy Therapeutics Ltd which both develop and sell allergy therapeutics.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. ChatGPT (GPT-5.5, OpenAI, https://chatgpt.com) was used to assist in the conceptual development and graphical layout of Figure 2. Moreover, the text was streamlined and revised using the same aid. All scientific content, interpretation, were created, verified, and approved by the authors.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
[内容请查看原文]